Shannon Witt
Primary Care · New Albany, INNPI 1841673753
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 46.0% of the total. Reporting peaked in 2021 at $774 and has fallen 98.1% since, to $14 in 2025.
Across 172 payments — averaging $11.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$946
- Gilead$250
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$155
- Alkermes, Inc.$115
- Neurocrine Biosciences, Inc.$81
- Teva Pharmaceuticals USA, Inc.$69
- plus $439 from 12 others
What the payments were for
- Food & beverage$2,056100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 108 | $946 |
| Gilead | 15 | $250 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $155 |
| Alkermes, Inc. | 6 | $115 |
| Neurocrine Biosciences, Inc. | 6 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $69 |
| Biohaven Pharmaceuticals, Inc. | 1 | $64 |
| AstraZeneca | 4 | $54 |
| Lilly USA, LLC | 3 | $47 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| GSK | 2 | $45 |
| Exact Sciences | 2 | $36 |
| Novo Nordisk | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $31 |
| Indivior Inc. | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
How this compares
$2,056 in reported general payments places this provider in the 85th percentile of 113 primary care providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisinopril | 46 | $263 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $245 |
| Metformin Hcl | 21 | $154 |
| Atorvastatin Calcium | 31 | $153 |
| Amlodipine Besylate | 23 | $106 |
| Levothyroxine Sodium | 13 | $105 |
| Hydrochlorothiazide | 15 | $56 |
Paid to pharmacies, not to this prescriber.
Other primary care in New Albany
- Jalyn GoolsbyNew Albany$4K
- Katrina MotleyIndianapolis$18K
- Stephanie BodamerBloomington$6K
- Candace KapranosGary$5K
- Ashley VirtMuncie$4K
- Lana HumeCarmel$3K
- Illia LeiberingTell City$3K
- Jiyoung ChaeWest Lafayette$3K
- Leigha Bowyer-JonesJeffersonville$3K
- Heather PickettNoblesville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.